RT Journal Article
SR Electronic
T1 Systems Immunology Approaches to Understanding Immune Responses in Acute Infection of Yellow Fever Patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.04.24306661
DO 10.1101/2024.05.04.24306661
A1 Gonçalves, André N. A.
A1 Costa, Priscilla R.
A1 Thomazella, Mateus V.
A1 Correia, Carolina A.
A1 Marmorato, Mariana P.
A1 Dias, Juliana Z. C.
A1 Silveira, Cassia G. T.
A1 Maestri, Alvino
A1 Cerqueira, Natalia B.
A1 Moreira, Carlos H. V.
A1 Buccheri, Renata
A1 Félix, Alvina C.
A1 Martins, Felipe M.
A1 Maso, Vanessa E.
A1 Ferreira, Frederico M.
A1 Araújo, José D. A.
A1 Vasconcelos, Amanda P.
A1 Gonzalez-Dias, Patrícia
A1 Sékaly, Rafick-Pierre
A1 Cabral-Marques, Otavio
A1 Coelho-dos-Reis, Jordana G. A.
A1 Ferreira, Daniela M.
A1 Kallas, Esper G.
A1 Nakaya, Helder I.
YR 2024
UL http://medrxiv.org/content/early/2024/05/07/2024.05.04.24306661.abstract
AB In the 2018 yellow fever (YF) outbreak in Brazil, we generated new transcriptomic data and combined it with clinical and immunological data to decode the pathogenesis of YF. Our analysis of 79 patients highlighted distinct gene expression patterns between acute YF infections, other viral infections, and the milder infection induced by the live-attenuated YF-17D vaccine. We identified a critical role for low-density, immature neutrophils in severe outcomes, marked by the downregulation of genes such as PADI4, CSF3R, and ICAM1 in deceased patients. These genes are essential for neutrophil migration and maturation, suggesting their pivotal role in disease progression. Furthermore, our study revealed a complex interaction among inflammation-related genes: increased expression of CXCL10 in the acute phase was accompanied by decreased expression of IL-1b and an increase in IL1R2, a decoy receptor that binds to IL-1 to inhibit its activity. The diminished expression of HLA class II genes suggests an impairment in antigen presentation. These insights underscore the delicate balance of immune responses in YF pathogenesis and provide a foundation for future therapeutic and diagnostic advancements in managing YF.Highlights● PBMC transcriptome analysis in acute YFV highlights different immune responses between survivors and deceased patients.● Decreased expression of HLA class II genes in dendritic cells of deceased YFV patients indicates a critical impairment in antigen presentation and innate immunity.● Elevated B cell activation markers, such as BLNK and TNFRSF13B, in fatal YFV cases suggest an overactive, potentially dysregulated B cell response.● Increased expression of neutrophil-related genes, including DEFA1B and MMP9, in deceased YFV patients highlights neutrophils’ role in aggravating inflammation and tissue damage.Graphical AbstractCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by Bill & Melinda Gates Foundation, FAPESP, HCFMUSP, and USP. HIN is funded by FAPESP (grant numbers: #2017/50137-3, 2012/19278-6, 2018/14933-2, 2018/21934-5, and 2013/08216-2) and CNPq (313662/2017-7). We are particularly thankful to the following grants for fellows: ANAG (FAPESP Process 2019/13880-5), VEM (FAPESP Process 2019/16418-0), APV (FAPESP Process 2019/27146-1), MVT (FAPESP Process 2019/13713-1 and 2016/01735-2) and the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) (PhD Scholarships to CAC and MPM).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received ethical approval from the ethical review boards at the Institute of Infectology "Emilio Ribas" and Hospital das Clinicas, University of Sao Paulo (CAPPesq: 15477; CAAE: 59542216.3.1001.0068). All patients provided consent for participation, or their legal representatives did so when required, before being included in the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data generated in the current study are deposited at https://www.ncbi.nlm.nih.gov/BioProject (BioProject: PRJNA1017409) and will be made publicly accessible upon publication of the article in a peer-reviewed journal. https://dataview.ncbi.nlm.nih.gov/object/PRJNA1017409 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE243442 https://yellowfeverdb.sysbio.tools